Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis

S van Meer, KJ van Erpecum, Dave Sprengers, HJ Klumpen, PLM Jansen, J.N.M. IJzermans, PD Siersema, Rob de Man, J Verheij

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Objective The risk of hepatocellular carcinoma (HCC) is increased in patients with metabolic syndrome (MS), possibly related to nonalcoholic fatty liver disease (NAFLD). As histological features of NAFLD may regress in cirrhosis, we compared steatosis versus steatohepatitis in the nontumoral liver of noncirrhotic HCC patients. Patients and methods A retrospective clinicopathological analysis was carried out in 91 noncirrhotic HCC patients. Patients were divided into three subgroups: that is, patients with: (1) MS without other risk factors for underlying liver disease, (2) no underlying risk factors, or (3) other risk factors (with or without MS). The NAFLD activity score (NAS) less than 3 was classified as no steatohepatitis, NAS 3-4 as borderline steatohepatitis, and NAS 5 or more as definite steatohepatitis. Results Eleven (12%) patients had MS without other risk factors (group 1). In the nontumoral liver, significant steatosis (>= 5% of hepatocytes) was generally present (in 10/11 patients), with mild lobular inflammation and absence of ballooning in most cases. Absence of steatohepatitis, borderline steatohepatitis, and definite steatohepatitis were found in 55, 45, and 0% of cases, respectively. In groups 2 and 3, significant steatosis was frequently present (in 16/37 and 21/43 patients, respectively). Absence of steatohepatitis, borderline steatohepatitis, and definite steatohepatitis were found in 84, 16, and 0% of cases (group 2), respectively, in 77, 23, and 0% of cases (group 3). Conclusion In noncirrhotic HCC patients, histological steatosis was frequently present, whereas overt steatohepatitis did not occur. These findings may be relevant for HCC pathogenesis in NAFLD. Eur J Gastroenterol Hepatol 28:955-962 Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)955-962
Number of pages8
JournalEuropean Journal of Gastroenterology & Hepatology
Volume28
Issue number8
DOIs
Publication statusPublished - 2016

Cite this